Last reviewed · How we verify
NCT03443908
Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer
trial testing CPAP in Lung Cancer. Withdrawn.
13 May 2019
Quick facts
| Lead sponsor | Mark M. Fuster, MD |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 17 November 2017 |
| Primary completion | 13 May 2019 |
| Estimated completion | 13 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CPAP
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Mark M. Fuster, MD
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sleep-disordered breathing at night is a common medical problem. It leads to daytime fatigue, impairment in concentration and daily activities, and a higher risk of cardiovascular disease and life-threatening events. A particularly common form is obstructive sleep apnea (OSA), and it is usually treatable with a high rate of patient satisfaction and improved quality of life using a continuous positive airway pressure (CPAP) device. Treatment of this condition improves nighttime low-oxygen levels by ensuring patency of the upper airways. Research shows that in cancer, sleep disordered breathing is frequent. Low oxygen levels overnight may cause tumors to grow: tumors deprived of oxygen grow more blood vessels to try to get more oxygen, and growing more blood vessels makes the tumor grow. This study aims to examine how treating sleep-disordered breathing may lessen blood-flow to lung tumors, and thus serve to ultimately block tumor growth. Participants of this study will undergo sleep study and receive CPAP therapy as a part of routine care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
Verify or expand the search:
- PubMed search for NCT03443908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CPAP
Trials testing the same drug.
- NCT07417111 — Continued Pressure for Alveolar Protection (CPAP Trial) · NA · not yet recruiting
- NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
- NCT07504926 — A Randomised Feasibility Study of CPAP in Large Airway Collapse · NA · not yet recruiting
- NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
- NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03443908 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mark M. Fuster, MD
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03443908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing